Paper Details

  1. Home
  2. Paper Details

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.

Author: AlbertsSteven R, BoradMitesh J, ChakrabartiSakti, Fernandez-ZapicoMartin E, FosterNathan, FruthBriant, HartgersMindy, HogensonTara L, JinZhaohui, MahipalAmit, McWilliamsRobert R, NguyenTran, PitotHenry, QianShi, TellaSri Harsha, WashburnLeslie, Wee MaWen, WesslingJaclynn

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The combination of trifluridine/tipiracil plus irinotecan showed a promising 16-week progression-free survival rate of 37% in patients with refractory, advanced unresectable biliary tract carcinoma (BTC).
Paper Details　
Original Abstract of the Article :
BACKGROUND: We sought to determine the safety and efficacy of trifluridine/tipiracil in combination with irinotecan in a phase II trial setting for refractory, advanced unresectable biliary tract carcinoma (BTC). METHODS: A total of 28 patients (27 were evaluable) with advanced BTCs who progressed ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546810/

データ提供：米国国立医学図書館（NLM）

Trifluridine/Tipiracil Plus Irinotecan: A New Treatment Option for Biliary Tract Carcinoma

The field of oncology is constantly seeking new and effective treatments for cancer. This Phase II trial investigates the safety and efficacy of trifluridine/tipiracil in combination with irinotecan for patients with refractory, advanced biliary tract carcinoma (BTC). It's like exploring a new oasis in the vast desert of cancer treatment, searching for a source of relief and hope for patients facing this challenging diagnosis.

A Promising Combination Therapy for Biliary Tract Carcinoma

The trial results show that the combination of trifluridine/tipiracil plus irinotecan demonstrates potential as a treatment option for patients with refractory, advanced BTC. This finding offers a new pathway for treating this complex cancer, potentially improving outcomes for patients with limited treatment options. It's like discovering a hidden spring in the desert, providing a source of sustenance and strength for those in need.

Navigating the Complexities of Cancer Treatment

The trial highlights the importance of personalized medicine, recognizing that different treatment strategies may be more effective for different patients. It's like choosing the right caravan route through the desert, considering the unique challenges and capabilities of each individual traveler. The trial also underscores the need for further research to confirm these findings and to explore the optimal dosage and administration of this combination therapy. It's like mapping a new path through the desert, requiring additional exploration and refinement to ensure a safe and successful journey.

Dr.Camel's Conclusion

This Phase II trial provides encouraging evidence for the potential of trifluridine/tipiracil plus irinotecan as a treatment option for patients with refractory, advanced BTC. It's like discovering a new oasis in the desert, offering a glimmer of hope for patients facing this challenging disease.

Date :
  1. Date Completed 2023-10-04
  2. Date Revised 2023-10-05
Further Info :

Pubmed ID

37339254

DOI: Digital Object Identifier

PMC10546810

Related Literature

Article Analysis
・Effects of trifluridine and tipiracil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.